Members of the European Parliament are heading to the Netherlands to see whether the European Medicines Agency’s relocation process is going according to plan. The move follows Italian criticisms that the Dutch provided “incomplete” information about their readiness to host the agency.
The European Parliament is to send a delegation to Amsterdam on a “fact-finding mission” to ascertain whether the European Medicines Agency’s relocation to the Dutch capital is proceeding “as planned and with no interruption.” The visit will be led by the parliament’s rapporteur for the relocation, Italian MEP Giovanni La Via.
The new seat of the agency has to be approved by the parliament, and the idea of the visit to...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
